Convention vs. innovation III: The promise of stem cell therapy in Parkinson's disease remains bright
- 1 May 2025
- journal article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 136, 107849
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Host-to-graft propagation of inoculated α-synuclein into transplanted human induced pluripotent stem cell-derived midbrain dopaminergic neuronsRegenerative Therapy, 2024
- Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson's diseaseCell Stem Cell, 2023
- Dopaminergic pathways and resting-state functional connectivity in Parkinson’s disease with freezing of gaitNeuroImage: Clinical, 2021
- Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01Cell Stem Cell, 2021
- Intracerebroventricular Administration of hNSCs Improves Neurological Recovery after Cardiac Arrest in RatsStem Cell Reviews and Reports, 2020
- Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson’s DiseaseCNS Drugs, 2020
- Human ESC-Derived Dopamine Neurons Show Similar Preclinical Efficacy and Potency to Fetal Neurons when Grafted in a Rat Model of Parkinson’s DiseaseCell Stem Cell, 2014
- Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s diseaseNature, 2011
- Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trialThe Lancet Neurology, 2010
- A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's diseaseAnnals of Neurology, 2003